Patient Data
| Patient No. . | Sex/Age (yr) . | Diagnosis . | Treatment (mo) . | Platelets (109/L) . | Hb (g/L) . | MCHC (g/L) . | MCV (μm3) . | Symptoms at Diagnosis . |
|---|---|---|---|---|---|---|---|---|
| 1 | M/70 | ET | 0 | 675 | 164 | 321 | 85 | Headache, dizziness |
| 7 | 297 | 125 | 333 | 117 | ||||
| 2 | M/62 | ET | 0 | 1,485 | 143 | 324 | 90 | Visual disturbances |
| 7 | 297 | 133 | 330 | 122 | ||||
| 3 | M/40 | ET | 0 | 1,770 | 146 | 348 | 91 | Pulmonary hemorrhage |
| 7 | 736 | 142 | 326 | 101 | ||||
| 4 | F/66 | ET | 0 | 710 | 135 | 340 | 90 | Fatigue |
| 6 | 398 | 133 | 327 | 127 | ||||
| 5 | M/70 | MF | 0 | 663 | 100 | 340 | 89 | Fatigue, vertigo |
| 8 | 357 | 131 | 335 | 115 |
| Patient No. . | Sex/Age (yr) . | Diagnosis . | Treatment (mo) . | Platelets (109/L) . | Hb (g/L) . | MCHC (g/L) . | MCV (μm3) . | Symptoms at Diagnosis . |
|---|---|---|---|---|---|---|---|---|
| 1 | M/70 | ET | 0 | 675 | 164 | 321 | 85 | Headache, dizziness |
| 7 | 297 | 125 | 333 | 117 | ||||
| 2 | M/62 | ET | 0 | 1,485 | 143 | 324 | 90 | Visual disturbances |
| 7 | 297 | 133 | 330 | 122 | ||||
| 3 | M/40 | ET | 0 | 1,770 | 146 | 348 | 91 | Pulmonary hemorrhage |
| 7 | 736 | 142 | 326 | 101 | ||||
| 4 | F/66 | ET | 0 | 710 | 135 | 340 | 90 | Fatigue |
| 6 | 398 | 133 | 327 | 127 | ||||
| 5 | M/70 | MF | 0 | 663 | 100 | 340 | 89 | Fatigue, vertigo |
| 8 | 357 | 131 | 335 | 115 |
Patients' data before and after HU treatment. The MPD were ET, of which one was classified as MF. The age, sex, and months of HU treatment are given together with platelet count, Hb concentration, MCHC, and MCV. Note that these data are from Coulter counter measurements, by which MCV is indirectly generated from a pore conductivity.